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linear growth in children under 5 years of age in
developing countries: a meta-analysis of studies
for input to the lives saved tool
Aamer Imdad, Zulfiqar A Bhutta*
Abstract
Introduction: Zinc plays an important role in cellular growth, cellular differentiation and metabolism. The results of
previous meta-analyses evaluating effect of zinc supplementation on linear growth are inconsistent. We have
updated and evaluated the available evidence according to Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) criteria and tried to explain the difference in results of the previous reviews.
Methods: A literature search was done on PubMed, Cochrane Library, IZiNCG database and WHO regional data
bases using different terms for zinc and linear growth (height). Data were abstracted in a standardized form. Data
were analyzed in two ways i.e. weighted mean difference (effect size) and pooled mean difference for absolute
increment in length in centimeters. Random effect models were used for these pooled estimates. We have given
our recommendations for effectiveness of zinc supplementation in the form of absolute increment in length (cm)
in zinc supplemented group compared to control for input to Live Saves Tool (LiST).
Results: There were thirty six studies assessing the effect of zinc supplementation on linear growth in children < 5
years from developing countries. In eleven of these studies, zinc was given in combination with other micronutrients
(iron, vitamin A, etc). The final effect size after pooling all the data sets (zinc ± iron etc) showed a significant positive
effect of zinc supplementation on linear growth [Effect size: 0.13 (95% CI 0.04, 0.21), random model] in the developing
countries. A subgroup analysis by excluding those data sets where zinc was supplemented in combination with iron
showed a more pronounced effect of zinc supplementation on linear growth [Weighed mean difference 0.19 (95 % CI
0.08, 0.30), random model]. A subgroup analysis from studies that reported actual increase in length (cm) showed that a
dose of 10 mg zinc/day for duration of 24 weeks led to a net a gain of 0.37 (±0.25) cm in zinc supplemented group
compared to placebo. This estimate is recommended for inclusion in Lives Saved Tool (LiST) model.
Conclusions: Zinc supplementation has a significant positive effect on linear growth, especially when administered
alone, and should be included in national strategies to reduce stunting in children < 5 years of age in developing
countries.
Introduction
The association of zinc deficiency with growth retardation
and hypogonadism was first described in 1963 from Iran
[1] and is now well established from animal and human
studies demonstrating that zinc plays a critical role in cel-
lular growth, cellular differentiation and metabolism [2].
Several studies have been conducted to explore the
effect of zinc supplementation on children’s growth.
Although there have been several reviews published on
this topic, to date few meta-analyses have been pub-
lished in this regard [3-5]. The two meta-analyses by
Brown et al. [3,4] that included studies of zinc supple-
mentation in pre-pubertal children concluded that zinc
supplementation produces highly significant positive
effect on height gain. In contrast, a recent meta-analysis* Correspondence: zulfiqar.bhutta@aku.edu
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by Ramakrishnan et al. [5] concluded that zinc supple-
mentation was not associated with any significant posi-
tive effect on linear growth in children < 5 years of age.
We have reviewed the available literature and evalu-
ated the quality of included studies according to Child
Health Epidemiology Reference Group (CHERG) adapta-
tion of Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) criteria [6,7]. We
have updated the previous meta-analyses and have tried
to explore and explain the difference in results of the
above mentioned meta-analyses. We have also generated
an estimate for actual increase in length (cm) for input
into Lives Saved Tool (LiST) model for a standard dose
and duration of zinc supplementation in children < 5
years in developing countries.
Methods
Searching
To evaluate the effect of zinc supplementation on linear
growth, we conducted a literature search on PubMed,
Cochrane Library, IZiNCG database and WHO regional
databases library as well as a manual check of available
reviews and previous meta-analyses on the subject.
There was no language restriction. The following search
strategy was used for literature search: (“growth” OR
“height” OR “weight” OR “stunting” OR growt* OR
heigh* OR weigh* OR stuntin*) AND (“Zinc” OR “Zinc
sulphate”) and limited to “clinical trial” and “humans”.
The last date of search was March 3rd 2010.
Inclusion/exclusion criteria
The following inclusion criteria were used to identify the
studies for data abstraction: a) the study was a rando-
mized, placebo-controlled intervention trial conducted
in a developing country b) the subjects were children
less than 5 year of age c) the subjects were not prema-
ture infants; d) the subjects were free of chronic dis-
eases, such as sickle cell disease, cystic fibrosis, or severe
protein-energy malnutrition e) zinc was the only compo-
nent of the supplement that differed between treatment
groups and f) the supplemental zinc was provided for at
least ≥8 weeks. There was no restriction on dose of zinc
supplemented or formula used (e.g. Zinc sulphate or
Zinc Gluconate etc). The developing countries were
defined as countries with Gross National Income per
capita (GNI) below US$11,905, according to World
Bank [8]. We excluded studies where zinc was provided
in fortified food as this was considered a different inter-
vention that has been reviewed elsewhere [9].
Data abstraction and validity assessment
For quality assessment, data were abstracted into stan-
dardized forms using variables as study identifiers and
context, study design and limitations, intervention
specifics, and outcome effects [7]. Two authors entered
the data and discrepancies were removed, if found. Indi-
vidual studies were graded according to strengths and
limitations of the study. Studies received an initial score
of high if a randomized or cluster randomized trial and
then the grade was decreased for each study design lim-
itation, if applicable. A study was downgraded if there
were limitations in the conduct of studies e.g. inade-
quate methods of sequence generation or allocation
concealment and/or high loss to follow up (>20%). Risk
of bias in the included studies was assessed according to
latest Cochrane handbook and findings are presented in
Additional File 1. Finally each study was assigned a final
quality grade of “high” “moderate” “low” or “very low”
on the basis of strengths and limitations of study [6,10].
Studies receiving a grade of ‘very low’ were excluded
from the analysis. The grading of overall (pooled) evi-
dence was based on three components: (1) the volume
and consistency of the evidence; (2) the size of the
pooled effect and (3) the strength of the statistical evi-
dence reflected in the p-value [10]. A similar grading of
‘high’ ‘moderate’ ‘low’ and ‘very low’ was used for grad-
ing the overall evidence indicating the strength of an
effect of the intervention on specific health outcome
[10].
Quantitative data synthesis
The primary outcome was change in height [expressed
in cms or height-for-age Z score (HAZ)]. For studies
where mean change in height was not reported, it was
calculated as the difference of mean post- and pre-inter-
vention measurements. If studies did not report the
standard deviation (SD) for change in height, it was cal-
culated assuming that the correlation between the pre-
and post-test variances was equal to the average correla-
tion found in available studies. If studies reported the
standard error (SE), we calculated SD by multiplying SE
with square root of sample size. For studies that had dif-
ferent sample sizes at the beginning and the end of the
intervention, the lower value of the two was used in
analysis. The assessment of statistical heterogeneity in
the pooled analysis was done by visual inspection i.e.
the overlap of the confidence intervals among the stu-
dies, Chi square (P-value) of heterogeneity in the meta-
analyses and I2 statistics. A low P value (less than 0.10)
or a large chi-squared statistic relative to its degree of
freedom and I2 values greater than 50% were taken as
substantial and high heterogeneity. In situations of sub-
stantial or high heterogeneity being present, causes were
explored by sensitivity analysis and random effects
model were used.
In studies with factorial design i.e. (two or more inter-
vention comparisons carried out simultaneously in a
single study), only data in which zinc was the only
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difference between the two groups were included. For
example, for iron-zinc factorial trials, results were
included for comparisons of zinc only vs. placebo and
zinc plus iron vs. iron only. In case of cluster rando-
mized trials, cluster adjusted values were used.
Data were analyzed in two ways. In first analysis, we
pooled the studies to get a weighted mean difference
also called effect size. This value, also known as Cohen’s
effect size, is useful in meta-analyses because it elimi-
nates the problems of units of measurement (e.g. change
in height in cm or HAZ scores) and duration, which
may vary across studies [11,12]. These effect sizes were
calculated for individual studies by dividing the differ-
ence between the mean change in treatment and control
groups by the pooled standard deviation. Random effect
models were used for the primary analysis [13]. We did
a subgroup analysis for data sets where zinc was supple-
mented alone by excluding those data sets where it was
given in combination with iron. This was based on
results of some experimental studies that had shown
that iron may decrease the absorption of zinc when sup-
plemented together [14,15]. We hypothesized that the
preventive effect of zinc for stunting would be more
prominent if supplemented alone rather than in combi-
nation with iron.
In the second analysis, we pooled the studies reporting
change in height in cms to get a net change in length in
intervention group compared to control. We also did a
post hoc subgroup analysis for different daily dosages of
zinc supplementation to get a point estimate for inclu-
sion in the Live Saved Tool (LiST). More details about
this analysis are provided in the results section (Recom-
mendations for LiST model). All the meta-analyses were
conducted using software Review Manager version 5
[16].
Results
Trial flow
From literature search, 447 titles were identified (Fig: 1).
We scanned the titles and abstracts of the trials identi-
fied to exclude those that were obviously irrelevant,
retrieved the full text of the remaining trials, and identi-
fied relevant articles. Initially, 49 studies were selected
for detailed review. Five of these studies were not
included in the final analysis because the participants
were > 5 years of age [17-22]. Four studies were
excluded from analysis because they were from devel-
oped countries [23-26], as per objectives of LiST model.
Two studies were excluded because the duration of sup-
plementation was < 8 weeks [27,28]. One study was
excluded because it included only premature babies
[29]. Three studies were excluded because children had
severe protein energy malnutrition [30-32]. Finally, 36
studies were selected for data abstraction [33-68].
Study characteristics
Table 1 presents the characteristics of included studies.
All the included studies were randomized controlled
trials. In 25 studies zinc was supplemented alone while
in 11 studies some of the study groups also received
other micronutrients (iron, folic acid, vitamin A)
[47,51,52,54,58,59,61-63,65,68]. Mean initial height for
age Z score (HAZ) ranged from -2.91 [37] to -0.08 [33],
and the mean initial age ranged from less than one
month [50] to 55 months[40]. The average daily dose
(calculated by dividing the total weekly doses by 7) of
zinc supplementation ranged from 1 mg/day [41] to 20
mg/day [53] with a median of 10 mg/day. Most studies
(n = 28) provided the zinc supplements in the form of
zinc sulphate, although 5 used zinc acetate
[36,44,48,53,56] and 2 used zinc gluconate [34,55]. The
mean duration of intervention ranged from 8 weeks [41]
to 64 weeks [35] with a median of 24 weeks. All the
included studies were published between 1992 and 2009
(median: 1998). Fourteen of these studies were con-
ducted in Latin America or the Caribbean, 16 in Asia,
and 6 in Africa. Additional File 1 presents the risk of
bias table for included studies.
Effect on linear growth
Information on change in height (in cm or HAZ scores)
was available from 35 studies, which contained 47 group
wise comparisons. In study by Fahmida et al. 2007 [62],
only one data set was included in analysis (zinc alone
vs. placebo) because comparison groups for other data
sets (zinc + iron, zinc + iron + vitamin A) were not
appropriate (no iron only or iron + vitamin A group). In
study by Brown et al. 2007 [67], there were three inter-
vention groups i.e. placebo, zinc alone (solution form)
and zinc (in fortified food). We included comparison of
zinc (solution form) vs. placebo and not that of zinc in
fortified food vs. placebo. Iron was supplemented to
both groups in study by Alarcon et al. 2004 [51]. This
study had been included in analysis of zinc + iron vs.
iron alone and not that of zinc alone vs. control
comparison.
Our meta-analysis of available studies suggested that
zinc supplementation is associated with a net benefit on
linear growth. The estimated effect size (weighed mean
difference) for zinc supplementation on linear growth
including results from all data sets (zinc ± iron) was
0.13 [95% CI 0.04, 0.21] (Figure 2). When data sets with
zinc + iron were excluded from analysis, the final effect
size was 0.19 [95 % CI 0.08, 0.30] (Figure 3). We also
separately pooled results of data sets where zinc was
given in combination with Iron (data not shown). The
pooled estimate for zinc plus iron versus control was
-0.10 [95 % CI -0.21, 0.01]. These results were signifi-
cantly different from overall estimate (p=0.0001). This
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shows that zinc supplementation alone has more promi-
nent effects on length gain than when supplemented in
combination with iron. Due to this reason, we would
base our recommendations for LiST model on the basis
of results of zinc supplementation alone in the next
section.
Recommendations for LiST model
Results of effect size (weighed mean difference) are
interpreted as the percent of non-overlap of the inter-
vention group’s scores with those of the control group.
An effect size (ES) of 0.0 indicates that the distribution
of scores for the intervention group overlaps completely
with the distribution of scores for the control group,
and there is 0% non-overlap. An ES of 0.3 indicates a
non-overlap of 21.3% in the two distributions. Effect size
can be categorized as small (~0.2), medium (~0.5) or
large (~0.8) [11]. This shows that results of pooled effect
size can only be interpreted as percent of non-overlap of
results of two groups and an absolute quantitative esti-
mate cannot be generated in the form of units of mea-
surement [69].
In order to translate the observed weighed mean effect
size into practical recommendations, we reanalyzed the
subset of 28 studies that presented results in terms of
absolute height increments in centimeters. The pooled
results from 32 data sets of these studies showed a net
gain of 0.36 (±0.18) cm in the zinc supplemented group
compared to control in children < 5 years of age in
developing countries (Figure 4). The mean duration of
Studies reviewed with potential of 
eligibility         n= 49
Included studies: 36 
            Titles screened    447 
Extraction of studies not meeting our 
eligibility criteria  
Extracted after screening of titles and abstracts 
In 25 studies, 
supplementation 
was zinc alone. 
In 11 studies, 
some of the study 
groups also 
received other 
micronutrients 
like iron. 
Figure 1 Synthesis of study identification in review of the effects of zinc supplementation on growth.
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Table 1 Characteristics of included studies
Study ID (ref) Country Sample
size (n)
Mean initial
age (months)
Dose
(mg/
day)
Duration
(weeks)
Mean initial
height (cm)
Mean initial
HAZ score
Grade (High,
moderate and
low)
Hong 1992[33] China 102 0 5 24 50.0 -0.08 Moderate
Bates 1993[34] Gambia 110 18 70
(/2wk)
64 76.8 -1.57 High
Dirren 1994
[35]
Ecuador 96 32 10 64 81.6 -2.89 Moderate
Castillo-Duran
1995[36]
Chile 68 0 3 24 47.2 -1.36 Moderate
Ninh 1996[37] Vietnam 146 17.5 10 20 71.3 -2.91 Moderate
Sempertgui
1996[38]
Ecuador 50 42.3 10 9 _ -2.00 Moderate
Ruz 1997[39] Chile 102 39.8 10 56 95.6 -0.52 High
Rosado 1997 Mexico 109 28 20 52 83.4 -1.55 moderate
Gardner 1998
[42]
Jamaica 61 14 10 12 68.7 -2.85 High
Lira 1998[41] Brazil 137 0 1 and 5 8 _ _ Moderate
Kikafunda 1998
[40]
Uganda 155 55.8 10 24 103.3 -0.70 Moderate
Rivera 1998[43] Guatemala 89 7.5 10 28 63.7 -2.16 High
Smith 1999[44] Belize 51 44 70 24 _ _ High
Umeta 2000
[45]
Ethopia 100 9.6 10 24 69.9 -0.64 High
Castillo-Duran
2001[46]
Chile 150 0 5 52 50.3 -0.06 High
Dijkhuizen
2001[47]
Indonesia 238 4.2 10 24 61.2 -0.79 High
Osendarp 2002
[48]
Bangladesh 301 0.9 5 20 51.2 0.00 Low
Muller 2003
[49]
Burkina Faso 709 18.5 24 75.5 8.7 -1.55 High
Sur 2003[50] India 100 0 5 52 46.4 -1.70 High
Black 2004[52] Bangladesh 94 6.5 20 24 _ -1.20 Moderate
Black 2004[53] India 200 1 5 32 47.5 -1.20 Moderate
Lind 2004[54] Indonesia 340 6 10 24 _ -0.35 High
Alarcon 2004
[51]
Peru 213 17 3 18 76.8 -1.04 High
Penny 2004
[55]
Peru 246 19 10 24 76.4 -0.16 High
Gardner 2005
[57]
Jamaica 114 19 10 24 77.1 -1.65 Moderate
Brooks2005[56] Bangladesh 1665 5.3 70(/wk) 52 62.7 -1.10 High
Wasantwist
2006[61]
Thailand 304 4.5 10 24 62.3 -0.70 High
Silva 2006 [60] Brazil 58 23.5 10 16 _ -1.95 High
Berger 2006
[58]
Vietnam 391 5.9 10 24 63.8 -1.07 High
Olney 2006[59] Tanzania 433 8.8 10 52 _ -1.45 Moderate
Brown 2007
[67]
Peru 302 7.5 3 24 65.4 -1.19 High
Fahmida 2007
[62]
Indonesia 399 5 10 24 _ -0.99 High
Wuehler 2008
[64]
Ecuador 253 21 3,7and10 24 77.4 -2.30 High
Dijikhuizen
2008[63]
Multicentre trial (Thailand,
Veitnam and Indonesia)
2468 5.05 10 24 _ -0.82 High
Mozaffari-
Khosarvi 2009
[66]
Iran 85 38.8 5 24 _ -1.65 High
Walker 2009
[65]
Bangladesh 645 6.35 20 24 64.2 _ High
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supplementation in these studies was 7.03 months and
the dose ranged from 1 mg/day to 20 mg/day. The
weighed mean difference ‘effect size’ for these studies
was 0.23 (95 % CI 0.11, 0.36). In order to give a recom-
mendation with a specific dose/day and for a specific
duration, we did a post hoc subgroup analysis according
to different dosages of daily zinc supplementation
(Figure 5). This analysis showed that preventive zinc
supplementation in a dose of 10 mg/day has the most
significant effect on linear length in children < 5 years
¶ Black 2004 [study from Bangladesh[52]], *Black 2004 [ Study from India[53]]
Study or Subgroup
Hong 1992
Bates 1993
Dirren 1994
Castillo-Durran 1995
Ninh 1996
Sempertegui 1996
Rosado 1997 (Zn alone)
Rosado 1997 (Zn+Fe)
Ruz 1997
Lira 1998 (5 mg)
Rivera 1998
Gardner 1998
Kikafunda 1998
Lira 1998 (1 mg)
Smith 1999
Umeta 2000 (Stunted)
Umeta 2000 (Non-stunted)
Dijkhuizen 2001 (Zn+Fe)
Castillo -Durran 2001
Dijkhuizen 2001(Zn alone)
Osendarp 2002
Muller 2003
Sur 2003
Alarcon 2004 (Zn +Fe)
Black 2004 (Zn +Fe)¶
Lind 2004 (Zn + Fe)
Black 2004*
Black 2004 (Zn alone)¶
Penny 2004
Lind 2004 (Zn alone)
Gardner 2005
Brooks 2005
Berger 2006 (Zn + Fe)
Olney 2006 (Zn + Fe/F.A)
Wasantwisut 2006 (Zn +Fe)
Berger 2006 (Zn alone)
Silva 2006
Wasantwisut 2006(Zn only)
Olney 2006 (Zn alone)
Fahmida 2007 (Zn alone)
Brown 2007
Dijjkhuizen 2008 (Zn +Fe)
Wuehler 2008 (10 mg)
Dijkhuizen 2008(Zn alone)
Wuehler 2008 (7 mg)
Wuehler 2008 (3 mg)
Walker 2009 (Zn + Fe)
Walker 2009 (Zn alone)
Mozaffari-Khosarvi 2009
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 222.68, df = 48 (P < 0.00001); I² = 78%
Test for overall effect: Z = 2.85 (P = 0.004)
Weight
0.9%
1.8%
1.4%
1.5%
2.1%
1.3%
1.7%
1.8%
1.4%
1.9%
1.8%
1.5%
2.1%
1.9%
0.6%
1.7%
1.8%
2.4%
1.9%
2.2%
2.5%
2.7%
1.8%
2.3%
1.8%
2.5%
2.1%
1.8%
2.1%
2.5%
1.9%
2.7%
2.6%
1.9%
2.5%
2.6%
1.5%
2.5%
1.8%
2.6%
2.2%
2.8%
2.3%
2.8%
2.3%
2.3%
2.4%
2.4%
1.6%
100.0%
IV, Random, 95% CI
1.43 [0.67, 2.18]
-0.25 [-0.65, 0.15]
2.54 [1.99, 3.08]
0.54 [0.05, 1.02]
0.28 [-0.05, 0.60]
0.13 [-0.44, 0.70]
0.92 [0.50, 1.35]
-0.52 [-0.93, -0.12]
0.39 [-0.16, 0.93]
-0.19 [-0.57, 0.19]
0.20 [-0.22, 0.61]
-0.07 [-0.57, 0.43]
0.13 [-0.18, 0.45]
-0.14 [-0.52, 0.23]
1.51 [0.54, 2.48]
0.64 [0.21, 1.06]
0.27 [-0.13, 0.68]
-0.16 [-0.41, 0.09]
-0.43 [-0.81, -0.06]
-0.20 [-0.49, 0.08]
0.05 [-0.18, 0.28]
0.05 [-0.11, 0.20]
0.84 [0.43, 1.25]
0.29 [0.02, 0.56]
-0.23 [-0.64, 0.18]
-0.22 [-0.44, -0.00]
0.03 [-0.29, 0.35]
0.11 [-0.29, 0.52]
0.21 [-0.11, 0.54]
-0.05 [-0.26, 0.17]
-0.06 [-0.42, 0.31]
0.26 [0.11, 0.42]
-0.07 [-0.27, 0.13]
-0.08 [-0.45, 0.29]
0.04 [-0.18, 0.27]
0.12 [-0.08, 0.32]
0.00 [-0.52, 0.52]
0.25 [0.03, 0.48]
-0.31 [-0.70, 0.09]
0.08 [-0.13, 0.28]
0.00 [-0.30, 0.30]
0.00 [-0.11, 0.11]
-0.09 [-0.35, 0.18]
0.06 [-0.05, 0.17]
0.09 [-0.18, 0.37]
0.00 [-0.27, 0.27]
-0.04 [-0.28, 0.19]
-0.04 [-0.27, 0.20]
1.03 [0.58, 1.48]
0.13 [0.04, 0.21]
Year
1992
1993
1994
1995
1996
1996
1997
1997
1997
1998
1998
1998
1998
1998
1999
2000
2000
2001
2001
2001
2002
2003
2003
2004
2004
2004
2004
2004
2004
2004
2005
2005
2006
2006
2006
2006
2006
2006
2006
2007
2007
2008
2008
2008
2008
2008
2009
2009
2009
Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours experimental
Figure 2 Effect sizes for height gain in zinc intervention trials among children less than 5 years of age in developing countries. Final
estimate from 48 data sets of 36 studies. (Includes data sets with zinc + iron).
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of age [mean difference: 0.46cm (95 % CI 0.21, 0.71),
random model]. The results for dose of 5 mg/day [mean
difference 0.61 (95 % CI -0.28, 1.51), random model]
and that of 3mg/day [mean difference 0.05 (95 % CI
-0.25, 0.35) random model] were not statistically signifi-
cant. There was a significant statistical difference among
these subgroups (p=0.005). In the subset of studies
where zinc was supplemented in a dose of 10 mg/day,
( pp )
Study or Subgroup
Hong 1992
Bates 1993
Dirren 1994
Castillo-Durran 1995
Sempertegui 1996
Ninh 1996
Rosado 1997 (Zinc alone)
Ruz 1997
Rivera 1998
Gardner 1998
Lira 1998 (1 mg)
Kikafunda 1998
Lira 1998 (5 mg)
Smith 1999
Umeta 2000 (Non-stunted)
Umeta 2000 (Stunted)
Dijkhuizen 2001(Zn alone)
Castillo -Durran 2001
Rahman 2002 (Zinc alone)
Osendarp 2002
Sur 2003
Muller 2003
Black 2004 (Zinc alone)¶
Penny 2004
Black 2004*
Lind 2004 (Zinc alone)
Gardner 2005
Brooks 2005
Wasantwisut 2006
Silva 2006
Berger 2006 (Zinc alone)
Olney (Zinc alone)
Fahmida 2007
Wuehler 2008 (7 mg)
Wuehler 2008 (10 mg)
Dijkhuizen 2008
Wuehler 2008 (3 mg)
Mozaffari-Khosarvi 2009
Walker 2009 (Zinc alone)
Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 194.14, df = 38 (P < 0.00001); I² = 80%
Test for overall effect: Z = 3.49 (P = 0.0005)
Weight
1.3%
2.4%
1.9%
2.1%
1.8%
2.7%
2.3%
1.9%
2.3%
2.0%
2.5%
2.7%
2.5%
0.9%
2.4%
2.3%
2.9%
2.5%
3.1%
3.1%
2.4%
3.4%
2.4%
2.7%
2.7%
3.1%
2.5%
3.4%
3.1%
2.0%
3.2%
2.4%
3.2%
2.9%
3.0%
3.5%
2.9%
2.2%
3.1%
100.0%
IV, Random, 95% CI
1.43 [0.67, 2.18]
-0.25 [-0.65, 0.15]
2.54 [1.99, 3.08]
0.54 [0.05, 1.02]
0.13 [-0.44, 0.70]
0.28 [-0.05, 0.60]
0.92 [0.50, 1.35]
0.39 [-0.16, 0.93]
0.20 [-0.22, 0.61]
-0.07 [-0.57, 0.43]
-0.14 [-0.52, 0.23]
0.13 [-0.18, 0.45]
-0.19 [-0.57, 0.19]
1.51 [0.54, 2.48]
0.27 [-0.13, 0.68]
0.64 [0.21, 1.06]
-0.20 [-0.49, 0.08]
-0.43 [-0.81, -0.06]
0.03 [-0.19, 0.24]
0.05 [-0.18, 0.28]
0.84 [0.43, 1.25]
0.05 [-0.11, 0.20]
0.11 [-0.29, 0.52]
0.21 [-0.11, 0.54]
0.03 [-0.29, 0.35]
-0.05 [-0.26, 0.17]
-0.06 [-0.42, 0.31]
0.26 [0.11, 0.42]
0.25 [0.03, 0.48]
0.00 [-0.52, 0.52]
0.12 [-0.08, 0.32]
-0.31 [-0.70, 0.09]
-0.08 [-0.28, 0.12]
0.09 [-0.18, 0.37]
-0.09 [-0.35, 0.18]
0.06 [-0.05, 0.17]
0.00 [-0.27, 0.27]
1.03 [0.58, 1.48]
-0.04 [-0.28, 0.19]
0.19 [0.08, 0.30]
Year
1992
1993
1994
1995
1996
1996
1997
1997
1998
1998
1998
1998
1998
1999
2000
2000
2001
2001
2002
2002
2003
2003
2004
2004
2004
2004
2005
2005
2006
2006
2006
2006
2007
2008
2008
2008
2008
2009
2009
Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours experimental
Figure 3 Effect sizes for height gain in zinc intervention trials among children less than 5 years of age in developing countries. Final
estimate from 39 data sets of 34 studies. (Includes data sets with zinc supplementation alone).
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duration of supplementation was 6 months in all the
studies except in three studies [35,37,39]. In two of
these studies the supplementation continued for a year
[35,39] while in one study it was for 5 months [37]. In
the study by Brooks et al. [56] the supplementation also
continued until a year, however disaggregated data was
available for 6 months duration. We pooled results of
those studies where zinc was supplemented in a dose of
10 mg/day for duration of 24 weeks by excluding the
three above mentioned studies [35,37,39]. Combined
results from these studies showed a net gain in length
of 0.37 cm (±0.25) in zinc supplemented group com-
pared to placebo (Figure 6). Table 2 summarizes the
quality assessment and pooled estimate for this out-
come. The qualitative assessment of the available evi-
dence for the effect of zinc supplementation (10 mg/day
for 24 weeks) on linear growth was that of ‘moderate’
level. This qualitative grading for collective evidence is
*Black 2004 [ Study from India[53]]
Study or Subgroup
Hong 1992
Bates 1993
Dirren 1994
Castillo-Durran 1995
Ninh 1996
Ruz 1997
Rosado 1997 (Zn alone)
Kikafunda 1998
Lira 1998 (5 mg)
Gardner 1998
Lira 1998 (1 mg)
Rivera 1998
Smith 1999
Umeta 2000 (Stunted)
Umeta 2000 (Non-stunted)
Dijkhuizen 2001(Zn alone)
Osendarp 2002
Sur 2003
Muller 2003
Black 2004*
Penny 2004
Brooks 2005
Gardner 2005
Berger 2006 (Zn alone)
Wasantwisut 2006
Brown 2007
Dijkhuizen 2008(Zn alone)
Wuehler 2008 (3 mg)
Wuehler 2008 (10 mg)
Wuehler 2008 (7 mg)
Walker 2009 (Zn alone)
Mozaffari-Khosarvi 2009
Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 172.24, df = 31 (P < 0.00001); I² = 82%
Test for overall effect: Z = 3.98 (P < 0.0001)
Weight
2.9%
2.6%
5.6%
1.3%
0.9%
3.7%
5.6%
0.8%
2.7%
3.0%
2.0%
2.5%
3.5%
0.4%
0.5%
3.0%
4.1%
1.9%
4.8%
2.2%
4.1%
3.0%
0.7%
3.9%
3.8%
4.8%
5.4%
4.9%
4.9%
5.0%
3.4%
2.1%
100.0%
IV, Random, 95% CI
1.62 [0.88, 2.36]
-0.50 [-1.30, 0.30]
0.73 [0.62, 0.84]
1.50 [0.17, 2.83]
1.50 [-0.25, 3.25]
0.40 [-0.14, 0.94]
0.20 [0.11, 0.29]
0.77 [-1.04, 2.58]
-0.39 [-1.17, 0.39]
-0.10 [-0.81, 0.61]
-0.39 [-1.38, 0.60]
0.40 [-0.43, 1.23]
1.10 [0.51, 1.69]
4.10 [1.47, 6.73]
1.60 [-0.73, 3.93]
-0.50 [-1.20, 0.20]
0.10 [-0.35, 0.55]
2.30 [1.24, 3.36]
0.10 [-0.23, 0.43]
0.10 [-0.83, 1.03]
0.30 [-0.15, 0.75]
1.20 [0.49, 1.91]
-0.30 [-2.23, 1.63]
0.14 [-0.35, 0.63]
0.60 [0.07, 1.13]
0.00 [-0.31, 0.31]
0.10 [-0.09, 0.29]
0.00 [-0.31, 0.31]
-0.10 [-0.41, 0.21]
0.10 [-0.19, 0.39]
-0.10 [-0.71, 0.51]
2.36 [1.41, 3.31]
0.36 [0.18, 0.53]
Year
1992
1993
1994
1995
1996
1997
1997
1998
1998
1998
1998
1998
1999
2000
2000
2001
2002
2003
2003
2004
2004
2005
2005
2006
2006
2007
2008
2008
2008
2008
2009
2009
Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours experimental
Figure 4 Main gain in height (in cm) in zinc supplemented (alone) group compared to control. Data from 28 studies in the form 32
data sets irrespective of dose and duration of supplementation.
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based on the parameters such as volume and consis-
tency of the evidence, the size of the effect and the
strength of the statistical evidence for an association
between the intervention and outcome [10].
On the basis of qualitative grading of collective evi-
dence and specificity of intervention in terms of dose
and duration, we have recommended this estimate for
input to LiST model. This can be described as follows;
“preventive zinc supplementation in a dose of 10 mg/
day for 24 weeks in children < 5 years of age leads to a
net gain of 0.37cm in zinc supplemented group com-
pared to control in developing countries”.
*Black 2004 [ Study from India[53]] 
Study or Subgroup
4.1.1 Mean difference for length gain (cm): Dose 10 mg Zinc/day vs Control
Hong 1992
Dirren 1994
Ninh 1996
Ruz 1997
Gardner 1998
Kikafunda 1998
Rivera 1998
Smith 1999
Umeta 2000 (Stunted)
Umeta 2000 (Non-stunted)
Dijkhuizen 2001(Zn alone)
Muller 2003
Penny 2004
Gardner 2005
Brooks 2005
Wasantwisut 2006
Berger 2006 (Zn alone)
Wuehler 2008 (10 mg)
Dijkhuizen 2008(Zn alone)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 93.36, df = 18 (P < 0.00001); I² = 81%
Test for overall effect: Z = 3.55 (P = 0.0004)
4.1.2 Mean difference for length gain (cm): Dose 5 mg Zinc/day vs Control
Bates 1993
Lira 1998 (5 mg)
Osendarp 2002
Sur 2003
Black 2004*
Mozaffari-Khosarvi 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 1.07; Chi² = 39.47, df = 5 (P < 0.00001); I² = 87%
Test for overall effect: Z = 1.34 (P = 0.18)
4.1.3 Mean difference for length gain (cm): Dose 3 mg Zinc/day vs Control
Castillo-Durran 1995
Brown 2007
Wuehler 2008 (3 mg)
Walker 2009 (Zn alone)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 4.90, df = 3 (P = 0.18); I² = 39%
Test for overall effect: Z = 0.34 (P = 0.73)
Weight
5.2%
9.1%
1.7%
6.5%
5.4%
1.6%
4.6%
6.2%
0.8%
1.0%
5.4%
8.0%
7.1%
1.5%
5.4%
6.6%
6.8%
8.2%
8.8%
100.0%
16.9%
17.0%
18.6%
15.3%
16.1%
16.0%
100.0%
4.6%
38.9%
38.9%
17.6%
100.0%
IV, Random, 95% CI
1.62 [0.88, 2.36]
0.73 [0.62, 0.84]
1.50 [-0.25, 3.25]
0.40 [-0.14, 0.94]
-0.10 [-0.81, 0.61]
0.77 [-1.04, 2.58]
0.40 [-0.43, 1.23]
1.10 [0.51, 1.69]
4.10 [1.47, 6.73]
1.60 [-0.73, 3.93]
-0.50 [-1.20, 0.20]
0.10 [-0.23, 0.43]
0.30 [-0.15, 0.75]
-0.30 [-2.23, 1.63]
1.20 [0.49, 1.91]
0.60 [0.07, 1.13]
0.14 [-0.35, 0.63]
-0.10 [-0.41, 0.21]
0.10 [-0.09, 0.29]
0.46 [0.21, 0.71]
-0.50 [-1.30, 0.30]
-0.39 [-1.17, 0.39]
0.10 [-0.35, 0.55]
2.30 [1.24, 3.36]
0.10 [-0.83, 1.03]
2.36 [1.41, 3.31]
0.61 [-0.28, 1.51]
1.50 [0.17, 2.83]
0.00 [-0.31, 0.31]
0.00 [-0.31, 0.31]
-0.10 [-0.71, 0.51]
0.05 [-0.25, 0.35]
Year
1992
1994
1996
1997
1998
1998
1998
1999
2000
2000
2001
2003
2004
2005
2005
2006
2006
2008
2008
1993
1998
2002
2003
2004
2009
1995
2007
2008
2009
Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours control Favours experimenta
Figure 5 Forest plot for mean gain in height (cm) after zinc supplementation alone in children less than 5 years of age: Subgroup
analysis according to different dosages.
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Discussion
Effect of zinc supplementation on linear growth has
been evaluated previously [3-5]. The first and most
widely known meta-analysis evaluating the effect of zinc
supplementation on growth was conducted by Brown et
al in 2002 [4]. This review included studies with chil-
dren until pre-puberty and studies from both developing
and developed countries. Pooled results from 33 studies
showed that zinc supplementation had a highly signifi-
cant positive effect on linear growth (effect size = 0.350,
95% CI: 0.189, 0.511). In the latest review published by
the same authors [3], more studies have been added to
the previous (2002) analysis and the beneficial effect
remained significant [effect size = 0.170 (95% CI: 0.075,
0.264)]. In contrast, another meta-analysis by Ramak-
rishnan et al. based on 43 studies found no significant
Results for study by Brooks e al. 2005 is for six months supplementation. 
Study or Subgroup
Hong 1992
Gardner 1998
Rivera 1998
Kikafunda 1998
Smith 1999
Umeta 2000 (Non-stunted)
Umeta 2000 (Stunted)
Dijkhuizen 2001(Zn alone)
Muller 2003
Penny 2004
Brooks 2005
Gardner 2005
Berger 2006 (Zn alone)
Wasantwisut 2006
Wuehler 2008 (10 mg)
Dijkhuizen 2008(Zn alone)
Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 51.46, df = 15 (P < 0.00001); I² = 71%
Test for overall effect: Z = 2.87 (P = 0.004)
Weight
5.9%
6.1%
5.1%
1.7%
7.1%
1.1%
0.9%
6.1%
9.7%
8.5%
9.7%
1.5%
8.1%
7.7%
9.9%
10.9%
100.0%
IV, Random, 95% CI
1.62 [0.88, 2.36]
-0.10 [-0.81, 0.61]
0.40 [-0.43, 1.23]
0.77 [-1.04, 2.58]
1.10 [0.51, 1.69]
1.60 [-0.73, 3.93]
4.10 [1.47, 6.73]
-0.50 [-1.20, 0.20]
0.10 [-0.23, 0.43]
0.30 [-0.15, 0.75]
0.60 [0.27, 0.93]
-0.30 [-2.23, 1.63]
0.14 [-0.35, 0.63]
0.60 [0.07, 1.13]
-0.10 [-0.41, 0.21]
0.10 [-0.09, 0.29]
0.37 [0.12, 0.62]
Year
1992
1998
1998
1998
1999
2000
2000
2001
2003
2004
2005
2005
2006
2006
2008
2008
Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours control Favours experimental
Figure 6 Mean gain in height (cm) after 10 mg zinc supplementation alone for 24 weeks in children < 5 years of age in developing
countries.
Table 2 Qualitative assessment of Trials for effect of zinc supplementation on linear growth
Quality Assessment Summary of findings
Generalizability Pooled
Effect
Qualitative
Assessment
No. of studies Design Limitations Consistency Generalizability
to Population
of Interest
Generalizability
to intervention
of Interest
Mean
Difference
( 95 % CI)
High,
moderate,
low, very
low)
Effect of Zinc supplementation on linear growth: Zinc supplementation for a dose of 10 mg/day for a duration of 24 weeks
15
[33,40,42-45,47,49,55-58,61,63,64]
RCT In one study [49], dose was
not exact 10 mg/day but
was 12.5 mg/day.
Supplementation in one
study continued till 28
weeks [43].
Heterogeneity
71 %. Random
effect models
used.
All the studies
from
developing
countries
10 mg zinc/day
for 24 weeks
0.37(0.12-
0.62) cm
Moderate
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effect of zinc supplementation on linear growth [effect
size = 0.07 (95% CI: -0.03, 0.17)] in children < 5 years of
age [5]. Our results from included studies from develop-
ing countries and with children < 5 years of age showed
that preventive zinc supplementation (zinc ± iron) had a
significant effect on linear growth [Effect size = 0.13 (95
% CI 0.04, 0.21)]. If we include results from four
excluded studies from developed countries [23-26], the
effect size comes to be 0.14 (95% CI 0.05-0.22) and if
the results of studies with children > 5 years are
included, the estimate becomes 0.15 (95 % CI 0.07,
0.23).
Our results are in concordance with that of Brown et
al. 2009 [3] but at variance with the findings of Ramak-
rishnan et al 2009 [5]. What are the reasons for these
contradictory findings and the differences between these
reviews? The main differences were in inclusion and
exclusion criteria. We and Ramakrishnan et al (5)
included studies with children < 5 years, while Brown et
al. (3) also included children until pre-pubertal age.
Both Brown et al. (3) and we excluded studies where
zinc was supplemented in fortified foods, while Ramak-
rishanan et al. (5) included these as well. Brown et al.
(3) also excluded those studies where SD for change in
length was not reported in the paper; however we and
Ramakrishnan included those (5). Do these differences
explain the reasons for contradictory results? If we
include zinc fortified studies with our analysis (all coun-
tries), the estimated effect size becomes 0.15 (95 % CI
0.06, 0.20), which indicates that excluding zinc fortifica-
tion studies did not significantly alter the results and
direction of effect. Excluding children > 5 years also did
not change the results significantly as shown above. We
could not find any further explanation for the difference
in results of our analysis and these reviews.
Presentation of results in terms of absolute difference
in the growth increment is described in previous
reviews. In the previous review by Brown et al. in 2002
(4) data were analyzed in two ways i.e. pooled weighted
mean difference (results discussed above) and actual
increase in length (cm) [4]. In the second analysis, they
pooled results from 25 studies to get a net increment in
length of 0.73 (±0.98) cm in zinc supplemented group
compared to controls. These results were not however
described for any particular dose or duration and the
meta-views were also not provided to get an idea of the
contribution of each study. On the other hand we have
described pooled results for all the studies that reported
absolute increment in length and also did a subgroup
analysis for the most effective dose for a particular dura-
tion. This leads to an estimated effect size of 0.37
(±0.25) cm increase in linear growth in children <5
years, with a specific dose of 10 mg zinc/day for a dura-
tion of 24 weeks (Fig 3). The p-value for this estimate
was 0.005 and quality grade for the pooled evidence was
that of ‘moderate’ level. The most prominent contribu-
tion to this estimate comes from study by Umeta et al.
in stunted children [45]. This is understandable, as zinc
seems to have more prominent effect on growth in
stunted compared to non-stunted children [4]. If results
of this data set are omitted from analysis, the estimate
becomes 0.36 (± 0.26) cm. In any case, keeping in mind
the statistical significance, quality grade and specificity
of estimate, this seems to be the most suitable input to
LiST model, for an effect size estimate of zinc supple-
mentation in prevention of stunting in children < 5
years of age in developing countries.
What does an extra gain of 0.37 cm means clinically?
An average gain of this much in height would not be a
huge effect but we need to take into account that that a
single micronutrient would not be expected to result in
such a substantial benefit at the first place. The results
of this review confirms that preventive zinc supplemen-
tation indeed has an effect in promotion of growth of
young children but this has to be connected with more
comprehensive approaches that improve the diets of
small children in general to get a more substantial
effect. These efforts should especially focus on first two
years of life and there should be a special attention to
promote exclusive breastfeeding and practices of com-
plementary feeding in addition to correcting micronutri-
ent deficiencies. An analysis published in lancet
undernutrition series in 2008 showed that education
and counseling of caretakers in food-secure populations
can improve growth in height (WMD 0.25; 95% CI:
0.01, 0.49) and providing complementary food, with or
without education and counseling, can improve height
in food insecure populations (WMD 0.41; 95% CI: 0.05,
0.76) [70]. In an updated analysis for this series, we have
shown that provision of complementary food (±nutrition
counseling) lead to an extra gain of 0.54 cm (±0.38) and
education of mothers about complementary feeding can
lead to an extra gain of 0.49 cm (±0.50) in the interven-
tion group compared to control [71]. Thus, in order to
get full advantage of relatively small benefit of correcting
zinc deficiency, we must, at the same time, focus on
interventions to improve complementary feeding and
general nutritional status if the child. Future research
should focus on strategies where correction of micronu-
trient deficiencies should be a part of a more general
approach to improve the nutritional status of the child
in general.
Do zinc and iron interact significantly when supple-
mented simultaneously? It has been demonstrated from
several studies that iron and zinc have similar absorp-
tion and transport mechanisms [72]. Experimental stu-
dies have also shown that simultaneous supplementation
of iron and zinc may inhibit zinc absorption in these
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cells especially at high ratios of iron to zinc [14,15,73]. A
review by Walker et al. (64) on interaction of zinc and
iron in supplementation trials showed that combined
supplementation of zinc and iron did not affect the bio-
chemical status of zinc; however the data were not clear
regarding morbidity and growth outcomes. In our
review, subgroup analysis excluding studies in which
zinc was co-administered with iron showed an increase
in overall effect size confirming the likelihood of inter-
action (Fig 2). When we separately pooled these data
sets (zinc + iron), the pooled effect size showed a nega-
tive trend -0.10 [95 % CI -0.21, 0.01]. These results were
significantly different from overall estimate (p=0.0007).
These analyses strongly suggest that addition of iron
decreases the positive effect of zinc supplementation on
linear growth through potential interference with
absorption or bio-availability. We have, therefore, pre-
sently restricted our recommendation for zinc supple-
mentation to studies with zinc supplementation alone.
We used rigorous eligibility criteria for inclusion of
studies. For example, the minimum period of supple-
mentation should be ≥8 wk because shorter periods may
be insufficient for detecting a linear growth response.
Furthermore, we excluded studies of premature infants
and those suffering from chronic disease or severe pro-
tein-energy malnutrition as zinc requirements of these
children might differ considerably from those of unaf-
fected children [74,75]. We also excluded studies in
which zinc was supplemented in fortified food. Although
tracer-element experimental studies had shown that zinc
fortification of food increase total zinc absorption
[76-78], relatively few community studies have found
positive impacts of zinc fortification on serum zinc con-
centrations or functional indicators of zinc status [3].
There is also insufficient evidence for ideal food vehicle
for zinc fortification and also interaction of zinc with
other micronutrient when fortified in a single food [9].
Preventive zinc supplementation seems to be a safe
intervention. It has been suggested that high levels of zinc
intake may interfere with normal iron and copper metabo-
lism [76]. Although we did not specifically look at adverse
effects, results from previous reviews showed that preven-
tive zinc supplementation in physiological doses do not
significantly affect the indicators of iron (i.e. hemoglobin
and/or ferritin level) and/or copper metabolism [3].
Our review has certain limitations. As our recommen-
dations are limited to zinc supplementation alone vs.
control/placebo, these results may not be readily applic-
able to countries where there are on-going national sup-
plementation programs of iron-folate, for example,
India. We expect that policy makers will assess local
contexts and conditions while considering the feasibility
of zinc supplementation programs. We were unable to
identify any significant predictor of substantial
heterogeneity in the pooled data. There may be factors,
not examined by us, that might explain the observed dif-
ferences. These include initial HAZ score (prevalence of
stunting), mean initial age, baseline zinc deficiency, gen-
der and HIV prevalence [4,79-81]. Although there are
relatively large number of studies and a funnel plot for
zinc alone supplementation was relatively symmetrical
(data not shown), there may be possible publication bias.
In conclusion, our review suggests that zinc supple-
mentation has a positive effect on linear growth, espe-
cially when supplemented alone. Zinc supplementation
in a dose of 10 mg/day for duration of 24 weeks led to
an increase gain in length by 0.37 (± 0.25) cm among
children < 5 years of age in developing countries com-
pared to controls.
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